Show Me Your Care Plan! Developing Multidisciplinary Strategies to Optimize the First-line Care of Patients With mRCC

Register Now

August 8th, 6:30 pm - 8:30 pm EDT

Fee: Free

Overview

Seventy-nine thousand patients will be diagnosed with renal cell carcinoma (RCC) this year, and approximately 13,900 will die from the disease in the US alone. Early detection is associated with a better 5-year survival rate (SR); however, the 5-year SR drops drastically from localized disease (92.6%) to distant disease (11.7%). RCC management is undergoing rapid changes, and the numerous therapies available challenge health care professionals to keep up-to-date with an ever-expanding armamentarium.

During this live Show Me Your Care Plan! webcast, a panel of distinguished specialists will engage in spirted discussions about the latest data on current and emerging therapeutic strategies for the management of metastatic RCC and explore practical approaches to patient counseling and evidence-based strategies for the early detection and management of treatment-related adverse events. Case studies and lively panel discussions will place new developments into clinical context to help participants optimize care for patients with RCC.

Benefits of Attending

• Understand the latest treatment strategies available for patients with mRCC
• Learn effective approaches to educate patients about the disease, its treatment, and treatment-related adverse effects (AEs)
• Review evidence-based methods for early identification and management of treatment-related AEs
• Explore ways to facilitate patient engagement in clinical trials

Target Audience

This educational program is directed toward nurses, pharmacists, and other health care professionals interested in the treatment of renal cell carcinoma.

Learning Objectives

Upon completion of this activity, participants will be able to:

• Assess practice-changing evidence on current and emerging frontline treatment options for patients with renal cell carcinoma (RCC)
• Incorporate best practices for monitoring and mitigating adverse events associated with targeted therapies and immunotherapies used in the frontline treatment of patients with advanced/metastatic RCC
• Apply personalized strategies to counsel patients concerning their frontline treatment plan, including potential treatment-related toxicities and the proactive plan for their identification and management
• Evaluate emerging therapies in clinical trials that may provide additional frontline treatment options for patients with advanced/metastatic RCC

The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies. 

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.